CYCLACEL PHARMACEUTICALS INC (CYCC)

US23254L8019 - Common Stock

1.75  -0.03 (-1.69%)

After market: 1.82 +0.07 (+4%)

News Image
22 days ago - Cyclacel

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid...

News Image
a month ago - InvestorPlace

CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023

CYCC stock results show that Cyclacel Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image
a month ago - BusinessInsider

CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclacel Pharmaceuticals (NASDAQ:CYCC) just reported results for the fourth qua...

News Image
a month ago - Cyclacel

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – ...

News Image
a month ago - Cyclacel

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;

News Image
2 months ago - Cyclacel

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma

News Image
2 months ago - Cyclacel

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma...

News Image
2 months ago - Cyclacel

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;

News Image
2 months ago - Cyclacel

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;

News Image
3 months ago - Cyclacel

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;

News Image
3 months ago - Seeking Alpha

Cyclacel Pharmaceuticals files to sell 411K shares of common stock (NASDAQ:CYCC)

Cyclacel Pharmaceuticals files a prospectus for the proposed sale of 411,969 shares of their common stock, but it is not an offer to sell these securities.

News Image
3 months ago - InvestorPlace

RKLB Stock Alert: The $500 Million Reason Rocket Lab Is Moving Today

Rocket Lab stock is on the move Tuesday as investors in RKLB react to a new $515 million contract with Space Development Agency.

News Image
3 months ago - InvestorPlace

Unity Layoffs 2024: What to Know About the Latest U Job Cuts

Unity layoffs are on the way as the video game software company reveals plans to cut 1,800 jobs to focus on its core business.

News Image
3 months ago - InvestorPlace

Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?

Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance.

News Image
3 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!

News Image
4 months ago - Seeking Alpha

CYCC regains compliance with Nasdaq (NASDAQ:CYCC)

Cyclacel Pharmaceuticals regains compliance with minimum bid price requirement as per Nasdaq notification letter on January 4, 2024.

News Image
4 months ago - Cyclacel

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;

News Image
4 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!

News Image
4 months ago - Cyclacel

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;